INKON Life Technology Co Ltd
INKON Life Technology Co Ltd is a Chinese pharmaceutical company that develops and sells medical products, primarily in the healthcare services and equipment sector.
Business. INKON Life Technology Co Ltd (300143.SZ) is a healthcare services and equipment company primarily engaged in pharmaceutical activities. The firm operates within the Healthcare Facilities & Services industry, generating revenue through service-based models. Headquartered in China, the company is listed on the Shenzhen Stock Exchange. Specific operating segments and geographic breakdowns are not disclosed in the available data.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
INKON Life Technology Co Ltd (300143.SZ) is a healthcare services and equipment company primarily engaged in pharmaceutical activities. The firm operates within the Healthcare Facilities & Services industry, generating revenue through service-based models. Headquartered in China, the company is listed on the Shenzhen Stock Exchange. Specific operating segments and geographic breakdowns are not disclosed in the available data.
INKON Life Technology Co Ltd has a market capitalization of 7.79 billion CNY and a price-to-earnings ratio of 113.61, significantly above the industry median for pharmaceutical and healthcare services firms. The company's price-to-book ratio of 3.1 suggests a premium valuation relative to its book value. Free cash flow is negative at -40.64 million CNY, indicating that capital expenditures are outpacing operating cash flow.
Profitability metrics show a return on equity of 2.73% and a return on assets of 1.63%, both below the industry median for firms in the Healthcare Facilities & Services sector. Operating income of 160.91 million CNY and net income of 68.54 million CNY reflect a relatively narrow margin structure, with a gross profit margin of 26.93%.
The company's geographic and segment exposure is not disclosed in the available data, but its revenue concentration is likely within China, given its listing on the Shenzhen Stock Exchange. No material revenue diversification across regions or product lines is evident from the financial snapshot.
Looking ahead, the company is expected to maintain a stable revenue trajectory, with no significant growth or contraction indicated in the outlook. Capital expenditures of -226.64 million CNY suggest ongoing investment in infrastructure or expansion, but the negative free cash flow indicates that these investments are not yet generating positive cash returns.
The risk assessment highlights a medium liquidity risk, with a current ratio of 2.07 and a debt-to-equity ratio of 0.31. The company's net cash position is negative after subtracting total debt, which could limit its flexibility in responding to market pressures. Dilution risk is assessed as low, with no near-term pressure from share issuance or dilutive events.
Recent analyst estimates show a strong consensus, with a mean price target of 12.42 CNY and a mean recommendation of 1.00 (strong buy). This suggests that the market expects the company to outperform in the near term, despite its current valuation multiples.
- INKON Life Technology Co Ltd is trading at a high price-to-earnings ratio of 113.61, indicating a premium valuation.
- The company's return on equity of 2.73% is below the industry median for healthcare services firms.
- Free cash flow is negative at -40.64 million CNY, suggesting that capital expenditures are outpacing operating cash flow.
- Analysts have a strong buy consensus, with a mean price target of 12.42 CNY.
- The company's liquidity risk is assessed as medium, with a current ratio of 2.07 and a debt-to-equity ratio of 0.31.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,23 |
| Revenue | —no estimate | —no estimate | 2,4B CNY |
| Operating income | —no estimate | —no estimate | —no estimate |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- INKON Life Technology Co Ltd Market data — financials · 2026-05-26
- INKON Life Technology Co Ltd Market data — analyst estimates · 2026-05-26